Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Total Non-Current Liabilities (2019 - 2021)

Historic Total Non-Current Liabilities for IDEAYA Biosciences (IDYA) over the last 3 years, with Q3 2021 value amounting to $81.8 million.

  • IDEAYA Biosciences' Total Non-Current Liabilities fell 2278.02% to $81.8 million in Q3 2021 from the same period last year, while for Sep 2021 it was $81.8 million, marking a year-over-year decrease of 2278.02%. This contributed to the annual value of $100.0 million for FY2020, which is 69559.96% up from last year.
  • IDEAYA Biosciences' Total Non-Current Liabilities amounted to $81.8 million in Q3 2021, which was down 2278.02% from $88.1 million recorded in Q2 2021.
  • Over the past 5 years, IDEAYA Biosciences' Total Non-Current Liabilities peaked at $105.9 million during Q3 2020, and registered a low of $11.9 million during Q3 2019.
  • Its 3-year average for Total Non-Current Liabilities is $53.1 million, with a median of $47.2 million in 2019.
  • As far as peak fluctuations go, IDEAYA Biosciences' Total Non-Current Liabilities surged by 79230.19% in 2020, and later plummeted by 2278.02% in 2021.
  • Quarter analysis of 3 years shows IDEAYA Biosciences' Total Non-Current Liabilities stood at $12.6 million in 2019, then skyrocketed by 695.6% to $100.0 million in 2020, then decreased by 18.18% to $81.8 million in 2021.
  • Its Total Non-Current Liabilities was $81.8 million in Q3 2021, compared to $88.1 million in Q2 2021 and $93.0 million in Q1 2021.